Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Adds 36 Drugs to NDRL Following Major Price Cuts

publication date: Jul 19, 2017
China will add 36 new drugs to its list of insurance-covered products after their manufacturers agreed to deep price cuts. China's Ministry of Human Resources said the cuts averaged 44% and reached a high of 70%. There were 31 western drugs -- 15 of them for cancer -- included in the list of newly added products and five Traditional Chinese Medicines. Big names for cancer in the adds included Roche's Herceptin, Avastin and MabThera; Celgene's Revlimid; J&J's Zytiga and Novartis' Afinitor. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital